Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  10.00 0.09% 11,060.00 11,038.00 11,040.00 11,176.00 11,002.00 11,034.00 2,453,557 16:35:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,668.9 -196.0 5.9 1,653.6 171,332

Astrazeneca Share Discussion Threads

Showing 5651 to 5672 of 5825 messages
Chat Pages: 233  232  231  230  229  228  227  226  225  224  223  222  Older
DateSubjectAuthorDiscuss
29/4/2022
08:45
What on earth is this guy chatting about?Shows what poorly researched inaccurate nonsense is banded about online: https://uk.finance.yahoo.com/news/astrazeneca-shares-covid-vaccine-sales-slump-080050224.html
riskonricky
27/4/2022
07:10
AstraZeneca PLC said Wednesday that its Enhertu drug has been granted a breakthrough therapy designation in the U.S. for the treatment of an unresectable or metastic breast cancer.

The FTSE 100 pharma giant said that Enhertu has been now been granted five breakthrough therapy designations, including three in breast cancer and one in both lung and gastric cancers.

The trial showed significant improvement in survival, the company said.

AstraZeneca developed Enhertu with Japanese pharmaceutical company Daiichi Sankyo Co.



Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix



(END) Dow Jones Newswires

April 27, 2022 02:49 ET (06:49 GMT)

waldron
25/4/2022
09:24
AstraZeneca PLC said Monday that its liver cancer treatment tremelimumab was accepted for priority review by U.S. federal health regulators.

The Anglo-Swedish pharmaceutical giant said the action date for the U.S. Food and Drug Administration's regulatory decision is expected in the fourth quarter of 2022.

The company said a Phase 3 study includes a dose of tremelimumab added to the immunotherapy Imfinzi, aiming to improve overall survival of patients with unresectable liver cancer.

"The Himalaya Phase III trial showed an unprecedented three-year overall survival in this setting with a single priming dose of tremelimumab added to Imfinzi, highlighting the potential for this regimen to improve longer-term survival outcomes," Susan Galbraith, AstraZeneca's executive vice president, oncology research and development, said.



Write to Michael Susin at michael.susin@wsj.com



(END) Dow Jones Newswires

April 25, 2022 02:48 ET (06:48 GMT)

adrian j boris
25/4/2022
06:49
Big news on the liver cancer trial this morning.
hotfinance14
24/4/2022
10:35
Https://www.fool.com/investing/2022/04/24/dividend-stocks-trouncing-the-market-are-they-buys/
grupo
19/4/2022
07:13
AstraZeneca PLC and Daiichi Sankyo Co. said Tuesday that Enhertu, a cancer treatment, has been accepted by the U.S. Food and Drug Administration for priority review for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease and the designation shortens the review period.

The pharmaceutical companies said the FDA based its decision on a pivotal Destiny-Lung01 trial which showed that Enhertu was the first HER2-directed therapy to show a strong and robust tumor response. It added that the FDA action date for their regulatory decision is during the third quarter of 2022.

The HER2 protein is expressed on the surface of many types of tumors and is one of many biomarkers expressed in breast cancer tumors.

"Enhertu is being further assessed in a comprehensive clinical development program evaluating efficacy and safety across multiple HER2-targetable cancers, including breast, gastric, lung and colorectal cancers," AstraZeneca said.



Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com



(END) Dow Jones Newswires

April 19, 2022 02:40 ET (06:40 GMT)

maywillow
12/4/2022
17:09
Filled the gaps nicely on the chart
gateside
12/4/2022
16:58
Had a superb run, just a bit of profit taking.
montyhedge
12/4/2022
11:44
ASTRAZENECA : Buy rating from Berenberg
04/12/2022 | 12:40pm BST

In a research note published by Luisa Hector, Berenberg advises its customers to buy the stock. The target price is revised upwards from GBX 10000 to GBX 12000.

waldron
08/4/2022
18:40
have not followed this stock for a while - what a mistake . now chart shows a NOR situation and how long is s piece of string !
arja
08/4/2022
15:27
Long term, holder, yes institutions must be piling in with new cash.
chc15
08/4/2022
15:03
Institutions I assume. I bought a fair amount, in my terms before the rise and am happily holding.
our haven
08/4/2022
14:45
I'm buying it...
mapocho
08/4/2022
13:43
Amazed there is so little chatter on this board. Up 25% in a month. Keeping entire FTSE up whilst Europe and US markets fall.But no interest here? Who is buying this?
paa65
07/4/2022
06:37
James Gordon from JP Morgan retains his positive opinion on the stock with a Buy rating.


The target price is reviewed upwards from GBX 10000 to GBX 12000.

la forge
06/4/2022
16:00
Analysts at Deutsche Bank hiked their target price for AstraZeneca shares from 10,500.0p to 11,500.0p, telling clients it saw no reason to tilt towards so-called 'value' names in the space and away from 'growth'.

Deutsche Bank conceded that an environment of rising interest rates would normally hardly be seen as auguring positively for a defensive sector to outperform.

However, DB highlighted that these weren't exactly normal times.

"This being a geopolitically-challenged stagflationary-susceptible situation, normal perhaps doesn't apply and indeed pharma has had a strong relative start to the year that may well continue," explained DB.

Within the sector, more highly-valued growth names such as AstraZeneca and Novo Nordisk had been the standout outperformers, versus the likes of GlaxoSmithKline, Novartis or Sanofi.

misca2
06/4/2022
09:09
Deutsche Bank raises AstraZeneca price target to 11,500 (10,500) pence - 'buy'
philanderer
05/4/2022
15:24
As mentioned, big momentum here, institutions buying at this level, so why sell.
chc15
05/4/2022
14:59
WD Waldron, good forecast!
dudishes
05/4/2022
06:15
Todays the day it might well break thru an important Resistence level
waldron
05/4/2022
06:14
(MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Monday its AZD8233 drug at 50-milligram dose lowered the levels of low-density lipoprotein cholesterol by 73% among people with high-risk hypercholesterolemia, meeting the main goal of a phase 2b study.

The dose-ranging clinical trial, dubbed Etesia, evaluated AZD8233 at 15 mg, 50 mg and 90 mg doses administered monthly via subcutaneous injection within a 12-week period.

Results showed that the drug also cut the PCSK9 enzyme levels by 89%, with sustained reductions observed over the dosing intervals. A decrease in PCSK9 raises LDL receptor levels, which in turn lowers cholesterol levels in the bloodstream, reducing the risk of developing heart disease.

The safety, efficacy and tolerability of AZD8233 in hypercholesterolemia are being examined in the Solano phase 2b trial, with results expected later in the year.

AstraZeneca gained nearly 1% on Monday's close.

Price (GBP): £10142.00, Change: £+66.00, Percent Change: +0.66%

waldron
31/3/2022
17:44
Mind u, mkts going down after putins demands, so taking profits not a bad thing.
chc15
Chat Pages: 233  232  231  230  229  228  227  226  225  224  223  222  Older
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221129 21:06:43